Addressing challenges associated with long‐term topical treatment and benefits of proactive management in patients with psoriasis

por Lebwohl, M., Thaçi, D., Warren, R.B.
Publicado 2021

Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest

por Reich, K., Mrowietz, U., Radtke, M. A., Thaci, D., Rustenbach, S. J., Spehr, C., Augustin, M.
Publicado 2015

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, control...

por Thaçi, D., Kimball, A., Foley, P., Poulin, Y., Levi, E., Chen, R., Feldman, S.R.
Publicado 2016

Qualität der dermatologischen Versorgung von Neurodermitis in Deutschland – keine Verbesserung der Indikatoren nach 10 Jahren

por Langenbruch, A., Mohr, N., Abeck, F., Schmitt, J., Ständer, S., Werfel, T., Thaçi, D., Weidinger, S., Augustin, M.
Publicado 2021

Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial

por Thaçi, D., Eyerich, K., Pinter, A., Sebastian, M., Unnebrink, K., Rubant, S., Williams, D. A., Weisenseel, P.
Publicado 2021

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis...

por Gerdes, S., Thaçi, D., Griffiths, C.E.M., Arenberger, P., Poetzl, J., Wuerth, G., Afonso, M., Woehling, H.
Publicado 2017

A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with modera...

por Reich, K., Augustin, M., Thaçi, D., Pinter, A., Leutz, A., Henneges, C., Schneider, E., Schacht, A., Dossenbach, M., Mrowietz, U.
Publicado 2019

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Stu...

por Bissonnette, R., Luger, T., Thaçi, D., Toth, D., Lacombe, A., Xia, S., Mazur, R., Patekar, M., Charef, P., Milutinovic, M., Leonardi, C., Mrowietz, U.
Publicado 2018

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)

por Gordon, K.B., Warren, R.B., Gottlieb, A.B., Blauvelt, A., Thaçi, D., Leonardi, C., Poulin, Y., Boehnlein, M., Brock, F., Ecoffet, C., Reich, K.
Publicado 2020

Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health‐related quality of life from two randomized phase 3 studies

por Merola, J.F., Papp, K.A., Nash, P., Gratacós, J., Boehncke, W.H., Thaçi, D., Graham, D., Hsu, M‐A., Wang, C., Wu, J., Young, P.
Publicado 2020

The German National Program on Psoriasis Health Care 2005–2015: results and experiences

por Augustin, M., Eissing, L., Langenbruch, A., Enk, A., Luger, T., Maaßen, D., Mrowietz, U., Reich, K., Reusch, M., Strömer, K., Thaçi , D., von Kiedrowski, R., Radtke, M. A.
Publicado 2016

Quality of life and patient‐perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed‐dose combination Cal/BD foam: A post‐hoc analys...

por Jalili, A., Calzavara‐Pinton, P., Kircik, L., Lons‐Danic, D., Pink, A., Tyring, S., de la Cueva, P., Gooderham, M., Segaert, S., Nyholm, N., Thoning, H., Petersen, B., Thaçi, D.
Publicado 2021

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study

por Thaçi, D., Papp, K., Marcoux, D., Weibel, L., Pinter, A., Ghislain, P.‐D., Landells, I., Hoeger, P.H., Unnebrink, K., Seyger, M.M.B., Williams, D.A., Rubant, S., Philipp, S.
Publicado 2019

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 1...

por Reich, K., Warren, R.B., Iversen, L., Puig, L., Pau‐Charles, I., Igarashi, A., Ohtsuki, M., Falqués, M., Harmut, M., Rozzo, S., Lebwohl, M.G., Cantrell, W., Blauvelt, A., Thaçi, D.
Publicado 2019

Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials

por Strober, B.E., Gottlieb, A.B., van de Kerkhof, P.C.M., Puig, L., Bachelez, H., Chouela, E., Imafuku, S., Thaçi, D., Tan, H., Valdez, H., Gupta, P., Kaur, M., Frajzyngier, V., Wolk, R.
Publicado 2018

International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale

por Abuabara, Katrina, Silverberg, Jonathan I, Simpson, Eric L, Paller, Amy S, Eichenfield, Lawrence F., Bissonnette, Robert, Krueger, James, Harris, John E., Dalfonso, Laura, Watkins, Stephanie E, Crawford, Julie M, Thaçi, D, Guttman-Yassky, Emma
Publicado 2020

Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a...

por Silverberg, J.I., Simpson, E.L., Ardeleanu, M., Thaçi, D., Barbarot, S., Bagel, J., Chen, Z., Eckert, L., Chao, J., Korotzer, A., Rizova, E., Rossi, A.B., Lu, Y., Graham, N.M.H., Hultsch, T., Pirozzi, G., Akinlade, B.
Publicado 2019

Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa stud...

por Cork, M.J., Thaçi, D., Eichenfield, L.F., Arkwright, P.D., Sun, X., Chen, Z., Akinlade, B., Boklage, S., Guillemin, I., Kosloski, M.P., Kamal, M.A., O’Malley, J.T., Patel, N., Graham, N.M.H., Bansal, A.
Publicado 2020

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension

por Cork, M.J., Thaçi, D., Eichenfield, L.F., Arkwright, P.D., Hultsch, T., Davis, J.D., Zhang, Y., Zhu, X., Chen, Z., Li, M., Ardeleanu, M., Teper, A., Akinlade, B., Gadkari, A., Eckert, L., Kamal, M.A., Ruddy, M., Graham, N.M.H., Pirozzi, G., Stahl, N., DiCioccio, A.T., Bansal, A.
Publicado 2019